{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T03:18:48Z","timestamp":1779333528231,"version":"3.51.4"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The efficacy of oral clodronate 800 mg daily to reduce vertebral fractures was studied in 593 women with postmenopausal or secondary osteoporosis. The incidence of vertebral fractures was significantly reduced by 46%. The effect was not modified by the underlying cause of osteoporosis or other baseline factors including bone mineral density, QUS, weight, and smoking.<\/jats:p>\n               <jats:p>Introduction: This study aimed to determine if the bisphosphonate, clodronate (Bonefos), reduced the incidence of vertebral fractures in osteoporotic women.<\/jats:p>\n               <jats:p>Materials and Methods: Women fulfilling the WHO criteria for osteoporosis at the lumbar spine (T-score \u2264 \u22122.5) and\/or with at least one prevalent vertebral fracture were recruited to a 3-year double-blind, placebo-controlled study. A total of 593 patients were randomized to two strata comprised of women with postmenopausal osteoporosis (I, n = 483) and secondary osteoporosis (II, n = 110). They received either clodronate 800 mg daily orally (n = 292) or an identical placebo (n = 301). All patients received a calcium supplement of 500 mg daily. BMD was measured at 6, 12, 24, and 36 months, and lateral spine radiographs were obtained at baseline and annually thereafter for vertebral morphometry.<\/jats:p>\n               <jats:p>Results: Treatment with clodronate was associated with a significant increase in mean spine BMD over 3 years (percent change from baseline, 4.35 \u00b1 6.34% versus 0.64 \u00b1 6.02% in the placebo group, p &amp;lt; 0.0001). At the hip, clodronate maintained total BMD, whereas a significant decrease was observed in the placebo group (percent change from baseline 0.70 \u00b1 5.67% versus \u22123.03 \u00b1 6.32% in the placebo group, p &amp;lt; 0.0001). The changes at the spine and hip were similar in both strata. Incident vertebral fractures at 3 years were observed in 63 women in the placebo group and 33 patients receiving clodronate (relative risk, 0.54; 95% CI, 0.37\u20130.80; p = 0.001). Clodronate significantly reduced vertebral fracture risk in both strata and in women with or without prior vertebral fracture at baseline. Nonvertebral osteoporosis-associated fractures occurred in 21 women in the placebo group and in 14 women treated with clodronate. Treatment was well tolerated, with no significant difference in adverse event rates, including esophagitis, during clodronate treatment.<\/jats:p>\n               <jats:p>Conclusion: We conclude that clodronate 800 mg daily is a safe and effective treatment to reduce fracture risk in women with osteoporosis, regardless of causation.<\/jats:p>","DOI":"10.1359\/jbmr.040116","type":"journal-article","created":{"date-parts":[[2006,4,27]],"date-time":"2006-04-27T07:02:13Z","timestamp":1146121333000},"page":"728-736","source":"Crossref","is-referenced-by-count":100,"title":["Clodronate Reduces Vertebral Fracture Risk in Women With Postmenopausal or Secondary Osteoporosis: Results of a Double-Blind, Placebo-Controlled 3-Year Study"],"prefix":"10.1093","volume":"19","author":[{"given":"Eugene","family":"McCloskey","sequence":"first","affiliation":[{"name":"Division of Genomic Medicine, The World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Selby","sequence":"additional","affiliation":[{"name":"Division of Genomic Medicine, The World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike","family":"Davies","sequence":"additional","affiliation":[{"name":"Division of Genomic Medicine, The World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Robinson","sequence":"additional","affiliation":[{"name":"Division of Genomic Medicine, The World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger M","family":"Francis","sequence":"additional","affiliation":[{"name":"Division of Genomic Medicine, The World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Adams","sequence":"additional","affiliation":[{"name":"Division of Genomic Medicine, The World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karthik","family":"Kayan","sequence":"additional","affiliation":[{"name":"Division of Genomic Medicine, The World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monique","family":"Beneton","sequence":"additional","affiliation":[{"name":"Division of Genomic Medicine, The World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarja","family":"Jalava","sequence":"additional","affiliation":[{"name":"Division of Genomic Medicine, The World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liisa","family":"Pylkk\u00e4nen","sequence":"additional","affiliation":[{"name":"Division of Genomic Medicine, The World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juha","family":"Kenraali","sequence":"additional","affiliation":[{"name":"Division of Genomic Medicine, The World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakari","family":"Aropuu","sequence":"additional","affiliation":[{"name":"Division of Genomic Medicine, The World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A","family":"Kanis","sequence":"additional","affiliation":[{"name":"Division of Genomic Medicine, The World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2009,12,2]]},"reference":[{"key":"2024013019205039500_bib1","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1359\/jbmr.2000.15.4.721","article-title":"Patients with prior fractures have an increased risk of future fractures: A summary of the literature and statistical synthesis","volume":"15","author":"Klotzbuecher","year":"2000","journal-title":"J Bone Miner Res"},{"key":"2024013019205039500_bib2","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1007\/s001980200084","article-title":"Does a fracture at one site predict later fractures at other sites? A British Cohort Study","volume":"13","author":"Van Staa","year":"2002","journal-title":"Osteoporos Int"},{"key":"2024013019205039500_bib3","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1200\/JCO.1993.11.1.59","article-title":"Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer","volume":"11","author":"Paterson","year":"1993","journal-title":"J Clin Oncol"},{"key":"2024013019205039500_bib4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2141.1998.00567.x","article-title":"A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults","volume":"100","author":"McCloskey","year":"1998","journal-title":"Br J Haematol"},{"key":"2024013019205039500_bib5","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/jnci\/90.9.704","article-title":"Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer","volume":"90","author":"Powles","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"2024013019205039500_bib6","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2002.11.080","article-title":"Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer","volume":"20","author":"Powles","year":"2002","journal-title":"J Clin Oncol"},{"key":"2024013019205039500_bib7","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1200\/JCO.1997.15.4.1341","article-title":"Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in premenopausal breast cancer patients","volume":"15","author":"Saarto","year":"1997","journal-title":"J Clin Oncol"},{"key":"2024013019205039500_bib8","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/bjc.1997.105","article-title":"Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens","volume":"75","author":"Saarto","year":"1997","journal-title":"Br J Cancer"},{"key":"2024013019205039500_bib9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/8756-3282(93)90240-B","article-title":"Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss","volume":"14","author":"Giannini","year":"1993","journal-title":"Bone"},{"key":"2024013019205039500_bib10","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0029-7844(96)00171-8","article-title":"Continuous and cyclical clodronate therapies and bone density in postmenopausal bone loss","volume":"88","author":"Giannini","year":"1996","journal-title":"Obstet Gynecol"},{"key":"2024013019205039500_bib11","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/8756-3282(95)00442-4","article-title":"Cyclical intravenous clodronate in postmenopausal osteoporosis: Results of a long-term clinical trial","volume":"18","author":"Filipponi","year":"1996","journal-title":"Bone"},{"key":"2024013019205039500_bib12","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s001980200131","article-title":"Prevention of bone loss by clodronate in early postmenopausal women with vertebral osteopoenia: A dose-finding study","volume":"13","author":"Valimaki","year":"2002","journal-title":"Osteoporos Int"},{"key":"2024013019205039500_bib13","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S8756-3282(00)00437-3","article-title":"Effects of clodronate on vertebral fracture risk in osteoporosis: A 1-year interim analysis","volume":"28","author":"McCloskey","year":"2001","journal-title":"Bone"},{"key":"2024013019205039500_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01626530","article-title":"A precise method for the assessment of tibial ultrasound velocity","volume":"6","author":"Orgee","year":"1996","journal-title":"Osteoporos Int"},{"key":"2024013019205039500_bib15","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s001980170112","article-title":"The burden of osteoporotic fractures: A method for setting intervention thresholds","volume":"12","author":"Kanis","year":"2001","journal-title":"Osteoporos Int"},{"key":"2024013019205039500_bib16","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/BF02106097","article-title":"European semi-anthropomorphomic spine phantom for the calibration of bone densitometers: Assessment of precision, stability and accuracy. The European Quantitation of Osteoporosis Study Group","volume":"5","author":"Pearson","year":"1995","journal-title":"Osteoporos Int"},{"key":"2024013019205039500_bib17","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"2024013019205039500_bib18","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"2024013019205039500_bib19","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"key":"2024013019205039500_bib20","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","article-title":"Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. FIT Research Group","volume":"85","author":"Black","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019205039500_bib21","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"2024013019205039500_bib22","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/archinte.162.10.1140","article-title":"Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis","volume":"162","author":"Maricic","year":"2002","journal-title":"Arch Intern Med"},{"key":"2024013019205039500_bib23","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1210\/jcem.87.8.8750","article-title":"Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial","volume":"87","author":"Delmas","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019205039500_bib24","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s001980050138","article-title":"Number and type of vertebral deformities: Epidemiological characteristics and relation to back pain and height loss. European Vertebral Osteoporosis Study Group","volume":"9","author":"Ismail","year":"1999","journal-title":"Osteoporos Int"},{"issue":"Suppl 2","key":"2024013019205039500_bib25","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/8756-3282(92)90193-Z","article-title":"The clinical consequences of vertebral compression fracture","volume":"13","author":"Silverman","year":"1992","journal-title":"Bone"},{"key":"2024013019205039500_bib26","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1056\/NEJM200008313430902","article-title":"Alendronate for the treatment of osteoporosis in men","volume":"343","author":"Orwoll","year":"2000","journal-title":"N Engl J Med"},{"key":"2024013019205039500_bib27","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1681\/ASN.V1271530","article-title":"Effect of ibandronate on bone loss and renal function after kidney transplantation","volume":"12","author":"Grotz","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"2024013019205039500_bib28","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med"},{"key":"2024013019205039500_bib29","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1359\/jbmr.2003.18.1.18","article-title":"The skeletal response to Teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis","volume":"18","author":"Marcus","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2024013019205039500_bib30","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1210\/jc.2002-020400","article-title":"Risedronate prevents new vertebral fractures in postmenopausal women at high risk","volume":"88","author":"Watts","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019205039500_bib31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1359\/jbmr.2002.17.1.11","article-title":"Bone turnover matters: The raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density","volume":"17","author":"Riggs","year":"2002","journal-title":"J Bone Miner Res"},{"key":"2024013019205039500_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1359\/jbmr.2002.17.1.1","article-title":"Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy","volume":"17","author":"Sarkar","year":"2002","journal-title":"J Bone Miner Res"},{"key":"2024013019205039500_bib33","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1210\/jcem.87.4.8415","article-title":"Changes in bone density and turnover explain the reductions in incidence of non-vertebral fractures that occur with antiresorptive agents","volume":"87","author":"Hochberg","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019205039500_bib34","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0002-9343(01)01124-X","article-title":"Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs","volume":"112","author":"Cummings","year":"2002","journal-title":"Am J Med"},{"key":"2024013019205039500_bib35","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1001\/archinte.160.22.3444","article-title":"Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: Three-year data from 2 double-blind, randomized, placebo-controlled trials","volume":"160","author":"Johnston","year":"2000","journal-title":"Arch Intern Med"},{"key":"2024013019205039500_bib36","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1185\/030079903125002009","article-title":"Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: A randomised, placebo-controlled study","volume":"19","author":"Hosking","year":"2003","journal-title":"Curr Med Res Opin"},{"key":"2024013019205039500_bib37","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1359\/jbmr.2003.18.7.1254","article-title":"Association between vertebral fracture and increased mortality in osteoporotic patients","volume":"18","author":"Jalava","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2024013019205039500_bib38","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJM199610033351403","article-title":"Esophagitis associated with the use of alendronate","volume":"335","author":"De Groen","year":"1996","journal-title":"N Engl J Med"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2Fjbmr.040116","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/19\/5\/728\/56475960\/5650190506.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/19\/5\/728\/56475960\/5650190506.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T15:06:27Z","timestamp":1710342387000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/19\/5\/728-736\/7592925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5,1]]},"references-count":38,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2009,12,2]]},"published-print":{"date-parts":[[2004,5,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.040116","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2004,5,1]]},"published":{"date-parts":[[2004,5,1]]}}}